Possible involvement of transthyretin in hippocampal β-amyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8)

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 88-95

  Doggui, Sihem ^a   Brouillette, Jonathan ^a   Chabot, Jean Guy ^a   Farso, Mark ^a   Quirion, Rémi ^a  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; Deposition of amyloid; Human amyloid precursor protein transgenic mouse; Morris water maze; Spatial learning; TgCRND8 mouse; Transthyretin

Indexed keywords

AMYLOID BETA PROTEIN; PREALBUMIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; HIPPOCAMPUS; LEARNING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPATIAL MEMORY; SURVIVAL RATE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LEARNING DISORDERS; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PREALBUMIN;

EID: 76749088922     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000285513     Document Type: Conference Paper

References (49)

1. Goedert M, Spillantini MG: A century of Alzheimer's disease. Science 2006; 314: 777-781.
2. Artero S, Tierney MC, Touchon J, Ritchie K: Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 2003; 107: 390-393.
3. Perry RJ, Hodges JR: Attention and executive deficits in Alzheimer's disease. A critical review. Brain 1999; 122: 383-404.
4. Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR: Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 2003; 126: 2350-2362.
5. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
6. Haass C: Take five-BACE and the- -secretase quartet conduct Alzheimer's amyloid- -peptide generation. EMBO J 2004; 23: 483-488.
7. Walsh DM, Selkoe DJ: A oligomer - a decade of discovery. J Neurochem 2007; 101: 1172-1184.
8. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak- Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349; 1991: 704-706. (Pubitemid 21912142)
9. Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, Moreau V, Charbonnier F, Didierjean O, Tardieu S, Penet C, Puel M, Pasquier F, Le Doze F, Bellis G, Calenda A, Heilig R, Martinez M, Mallet J, Bellis M, Clerget-Darpoux F, Agid Y, Frebourg T: Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet 1995; 4: 2373-2377.
10. Sherrington R, Rogaev EL, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J-F, Bruni AC, Montesi MP, Sorbi S, Rainero I Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH: Cloning of the gene bearing missense mutations in early- onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
11. Brouillette J, Quirion R: Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging 2008; 29: 1721-1732.
12. Sousa JC, Marques, F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA: Transthyretin influences spatial reference memory. Neurobiol Learn Mem 2007; 88: 381-385.
13. Chanoine JP, Alex S, Fang SL, Stone S, Leonard JL, Körhle J, Braverman LE: Role of transthyretin in the transport of thyroxine from the blood to the choroid plexus, the cerebrospinal fluid, and the brain. Endocrinology 1992; 130: 933-938.
14. Monaco HL: The transthyretin-retinolbinding protein complex. Biochim Biophys Acta 2000; 1482: 65-72.
15. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum insulin-like growth factor I regulates brain amyloid-levels. Nat Med 2002; 8: 1390-1397.
16. Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I: Blockade of the insulin- like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 2006; 27: 1618-1631.
17. Costa R, Gonçalves A, Saraiva MJ, Cardoso I: Transthyretin binding to A peptide impact on A fibrillogenesis and toxicity. FEBS Lett 2008; 582: 936-942.
18. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eseinberg M, Saunders AM, Roses AD, Goldgaber D: Transthyretin sequesters amyloid- protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994; 91: 8368-8372.
19. Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D: Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 2004; 11: 1-9.
20. Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA: Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 2007; 28: 713-718.
21. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T: Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A toxicity. Proc Natl Acad Sci USA 2008; 105: 2681-2686.
22. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA: Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APP SW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 2004; 24: 7707-7717.
23. Lazarov O, Robinson J, Tang Y-P, Hairston IS, Korade-Mirnics Z, Lee V M-Y, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS: Environmental enrichment reduces Alevels and amyloid deposition in transgenic mice. Cell 2005; 120: 701-713.
24. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE: Tabulation of human transthyretin (TTR) variants. Amyloid 2003; 10: 160-184.
25. Remes AM, Finnilä S, Mononen H, Tuominen H, Takalo R, Herva R, Majamaa K: Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology 2004; 63: 234-240.
26. Palha JA, Moreira P, Wisniewshi T, Frangione B, Saraiva MJ: Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 1996; 204: 212-214.
27. Cuenco KT, Friedland R, Baldwin CT, Guo J, Vardarajan B, Lunetta KL, Cupples LA, Green RC, DeCarli C, Farrer LA: Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. Neurobiol Aging DOI:10.1016/j.neurobiolaging. 2009.02.014.
28. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T: Comparative proteomics of cerebrospinal fluid in neuropathologicallyconfirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006; 28: 155-163.
29. Davidsson P, Sjogren M: Proteome studies of CSF in AD patients. Mech Ageing Dev 2006; 127: 133-137.
30. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH: Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007; 61: 120-129. (Pubitemid 46363839)
31. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I: Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 2008; 14: 17-25.
32. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR: An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology 2008; 70: 2212-2218.
33. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G: Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 1998; 425: 225-228.
34. Serot J-M, Christmann D, Dubost T, Couturier M: Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997; 63: 506-508.
35. Chishti, MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker, N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, St George-Hyslop P, Westaway D: Earlyonset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-21570.
36. Dudal S, Morissette C, Lacombe D, Tremblay P, Gervais F: Differences in the amyloidbeta induced inflammatory response in microglia from C57BL/6 and A/J strains of mice. J Neuroimmunol 2004; 153: 26-35.
37. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ: Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 1993; 90: 2375-2379.
38. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
39. Hyde LA, Kazdoba TM, Grilli M, Lozza G, Brusa R, Zhang Q, Wong GT, McCool MF, Zhang L, Parker EM, Higgins GA: Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice. Behav Brain Res 2005; 160: 344-355.
40. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HTJ, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
41. Hamilton JA, Benson MD: Transthyretin: a review from a structural perspective. Cell Mol Life Sci 2001; 58: 1491-1521.
42. Stein TD, Johnson JA: Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002; 22: 7380-7388.
43. Tsai KJ, Yang CH, Lee PC, Wang WT, Chiu MJ, Shem CKJ: Asymmetric expression patterns of brain transthyretin in normal mice and a transgenic mouse model of Alzheimer's disease. Neuroscience 2009; 159: 638-646.
44. Link CD: Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans . Proc Natl Acad Sci USA 1995; 92: 9368-9372.
45. Giunta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L: Transthyretin inhibition of amyloid beta aggregation and toxicity. Clin Biochem 2005; 38: 1112-1119.
46. Choi SH, Leight SN, Lee VM-Y, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia, SS: Accelerated A deposition in APPswe/PS1 E9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 2007; 27: 7006-7010.
47. Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, Kubota T, Harigaya Y, Shoji M, Maeda S: Transthyretin accelerates vascular A deposition in a mouse model of Alzheimer's disease. Brain Pathol 2009; 19: 48-57.
48. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Youkin SG, Borchelt DR: Mutant presenilins specifically elevate the levels of the 42 residue- amyloid peptide in vivo; evidence for augmentation of a 42-specific secretase. Hum Mol Genet 2004; 13: 159-170.
49. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K-H, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 94: 13287-13292.